Bumin Hospital
Seoul, South Korea
NCT Number: NCT07643233
To evaluate and compare the safety and pharmacokinetic profiles of "AJU-G721" (test drug) and "G721R" (reference drug) in healthy adult male subjects.
Trial opening soon.
Get Notified19 year–54 year
Male
Interventional
Phase 1
Seoul, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
AJU-G721
G721R
Time frame: 0 hour ~ 48 hour after drug administration
To assess the maximum observed plasma concentration (Cmax) of Tamsulosin.
Time frame: 0 hour ~ 48 hour after drug administration
To assess the plasma concentration-time curve from time 0 to the last measurable concentration (AUCt) of Tamsulosin
AJU Pharm Co., Ltd.
Industry
An Open-Label, Randomized, Fed, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of "AJU-G721" and "G721R" in Healthy Adult Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07643220
Moderate-to-severe Benign Prostatic Hyperplasia (BPH)
Seoul, South Korea
View Trial Details